The companies are developing a rapid, at-home colorectal cancer test that uses interstitial fluid as a sample type.

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

The firm reported growth across its immunodiagnostics and molecular diagnostics businesses as well as contributions from the firm's licensed technologies business.

Last week, readers were most interested in a story about Mursla's liver cancer test for detecting microRNA and protein targets within extracellular vesicles.

NEW YORK – Eight German associations are calling for changes to be made to the European In Vitro Diagnostics Regulation (IVDR ...

Labcorp will acquire multiple same-day testing labs and select technical assets from Incyte, including its main anatomic pathology lab in Spokane, Washington.

The proceeds will be used to launch a new diagnostic instrument, a breast cancer monitoring assay, and proprietary multiplex immunofluorescence reagent kits.

NEW YORK – Diagnostic companies saw their stock prices continue to decline in April, falling 4 percent after a 5 percent decline in March, and dipping even deeper than the broader market. The Top 30 ...

The former True Health Diagnostics executives were accused of participating in a scheme that paid Texas physicians for blood test referrals.

In one case, a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other, a firm paid and received kickbacks for unnecessary genetic testing.